On January 20, 2022 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE protein biologic technology platform, reported that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B. Riley Securities’ Virtual Oncology Conference (Press release, GT Biopharma, JAN 20, 2022, View Source [SID1234605626]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GT Biopharma Logo (PRNewsfoto/GT Biopharma, Inc.)

Details for the presentations are as follows:

B. Riley Oncology Conference
Date: January 27, 2022
Time: 9:30 A.M. EST
Webcast Participation: View Source

For additional information regarding the conference please contact B. Riley at [email protected].